Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.
A 14-day course of reverse hybrid therapy is as effective as bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infection, although the former is associated with fewer adverse events, according to the results of a trial.
Genotypic resistance-guided therapy is no better than traditional empiric therapy for treating patients with refractory Helibacter pylori infection. Researchers found no significant difference in eradication rate between the two strategies when used in the third-line setting.
The increasing resistance to certain antibiotics in Helicobacter pylori (H. pylori) eradication therapies is associated with a reduction in treatment efficacy in Asia-Pacific countries, and treatments should be adapted accordingly, according to a systematic review and meta-analysis.
High consumption of fish and egg appears to be negatively associated with successful Helicobacter pylori eradication therapy in H. pylori‒positive patients with gastritis and/or duodenal ulcers, a recent study has found.
The vonoprazan-based triple therapy is superior to proton pump inhibitor-based triple therapy in terms of Helicobacter pylori eradication, although the two regimens show comparable tolerability and incidence of adverse events, according to a review and meta-analysis.
Helicobacter pylori (H. pylori) infection is associated with conditions such as gastritis, peptic ulcer, gastric cancer, and certain types of lymphoma. A common presenting complaint among all these H. pylori-related illnesses is dyspepsia. Dr Desmond Wai from the Desmond Wai Liver and Gastrointestinal Diseases Centre, Mount Elizabeth Novena Specialist Centre, Singapore, speaks on the important role general practitioners (GPs) play in recognizing, diagnosing, and treating H. pylori.
The novel bismuth-containing quadruple therapy with metronidazole and amoxicillin appears to be an attractive alternative to classical therapy with tetracycline for Helicobacter pylori rescue treatment, according to a study. The former demonstrates comparable eradication rates with superior safety and compliance.
New drug application approved by US FDA as of 01 - 15 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.